Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB D TARTRATE versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB D TARTRATE versus RETEVMO.
NILOTINIB D-TARTRATE vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BCR-ABL tyrosine kinase inhibitor; binds to and inhibits the ATP-binding site of BCR-ABL, thereby inhibiting tyrosine kinase activity and downstream signaling pathways, leading to apoptosis in CML cells.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
400 mg orally twice daily, approximately 12 hours apart, with food.
160 mg orally twice daily
None Documented
None Documented
17 hours (terminal elimination half-life); supports once-daily dosing
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Fecal (93%), renal (4%)
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor